Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you

recruiting
3 987
countries
28
conditions
2 109

701 trials match your criteria

Papulopustular rosacea

Recruiting

Efficacy and safety of remibrutinib (LOU064) in adult patients with papulopustular rosacea: a randomized, double‑blind, placebo‑controlled Phase 2 trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib

Type 2 diabetes mellitus

Recruiting

A Phase III Randomized Double‑Blind Study of Elecoglipron for Adults with Type 2 Diabetes on Insulin

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004

Type 2 diabetes mellitus

Recruiting

A study to assess the effect of elecoglipron alone and in combination with dapagliflozin on blood sugar control in adults with Type 2 diabetes

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004

Type 2 diabetes mellitus

Recruiting

A Phase III Study of Elecoglipron Compared with Semaglutide for Adults with Type 2 Diabetes Mellitus

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004

Hidradenitis

Recruiting

Long-term Safety and Efficacy of Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib

Bladder transitional cell carcinoma+1

Recruiting

A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin

Cold urticaria

Recruiting

A study to evaluate the effectiveness of barzolvolimab in participants with cold urticaria and symptomatic dermographism

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Alopecia areata

Recruiting

A study to evaluate the effectiveness and safety of LAD603 in adults with severe to very severe alopecia areata

Investigational
Countries:GermanyGermany
  • Participants:18–64 years

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III Study of Survodutide in Adults with Compensated NASH Cirrhosis to Assess Liver Outcomes and Safety

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906

Metabolic dysfunction-associated steatohepatitis+1

Recruiting

A Phase III trial of BI 456906 weekly injections in adults with NASH and stage 2‑3 liver fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906

Chronic spontaneous urticaria

Recruiting

A study to evaluate the long-term safety and effectiveness of barzolvolimab in patients with chronic spontaneous urticaria

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.